Tenascin-C Downregulates Wnt Inhibitor Dickkopf-1, Promoting Tumorigenesis in a Neuroendocrine Tumor Model

Cell Reports

Volumn 5, Issue 2, 2013, Pages 482-492

  Saupe, Falk ^a,b,c   Schwenzer, Anja ^a,b,c   Jia, Yundan ^a,b,c,d   Gasser, Isabelle ^a,b,c   Spenlé, Caroline ^a,b,c   Langlois, Benoit ^a,b,c   Kammerer, Martial ^a,b,c   Lefebvre, Olivier ^a,b,c   Hlushchuk, Ruslan ^e   Rupp, Tristan ^a,b,c   Marko, Marija ^a,b,c   vanderHeyden, Michael ^a,b,c   Cremel, Gérard ^a,b,c   Arnold, Christiane ^a,b,c   Klein, Annick ^a,b,c   Simon Assmann, Patricia ^a,b,c   Djonov, Valentin ^e   Neuville Méchine, Agnès ^f   Esposito, Irene ^g   Slotta Huspenina, Julia ^g   Janssen, Klaus Peter ^g   deWever, Olivier ^h   Christofori, Gerhard ^d,i   Hussenet, Thomas ^a,b,c   Orend, Gertraud ^a,b,c,d   more..

^a Université de Strasbourg   (France)

^b UNIVERSITÉ DE STRASBOURG   (France)

^c FMTS Fédération de Médecine Translationnelle de Strasbourg   (France)

^d UNIVERSITY OF BASEL   (Switzerland)

^e UNIVERSITY OF BERN   (Switzerland)

^f HÔPITAL DE HAUTEPIERRE   (France)

^g TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^h GHENT UNIVERSITY HOSPITAL   (Belgium)

ⁱ Tumor Biology Team   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

DICKKOPF 1 PROTEIN; MESSENGER RNA; TENASCIN; DKK1 PROTEIN, MOUSE; SIGNAL PEPTIDE; WNT PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CANCER MODEL; CARCINOGENESIS; CELL SURVIVAL; CONTROLLED STUDY; DKK1 GENE; GENE EXPRESSION REGULATION; GENE TARGETING; GENETIC STABILITY; HUMAN; HUMAN TISSUE; INSULINOMA; LUNG METASTASIS; MICROMETASTASIS; MOUSE; NEUROENDOCRINE TUMOR; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; TNC GENE; TUMOR INVASION; TUMOR MICROENVIRONMENT; TUMOR PROMOTION; TUMOR VASCULARIZATION; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CELL TRANSFORMATION; DEFICIENCY; DISEASE MODEL; DOWN REGULATION; GENETICS; KNOCKOUT MOUSE; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE; UMBILICAL VEIN ENDOTHELIAL CELL;

MUS MUSCULUS;

ANIMALS; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; DISEASE MODELS, ANIMAL; DOWN-REGULATION; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NEOVASCULARIZATION, PATHOLOGIC; NEUROENDOCRINE TUMORS; SIGNAL TRANSDUCTION; TENASCIN; WNT PROTEINS;

EID: 84887015073     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2013.09.014     Document Type: Article

References (56)

1. Aguilera O., Fraga M.F., Ballestar E., Paz M.F., Herranz M., Espada J., García J.M., Muñoz A., Esteller M., González-Sancho J.M. Epigenetic inactivation of the Wnt antagonist DICKKOPF-1 (DKK-1) gene in human colorectal cancer. Oncogene 2006, 25:4116-4121.
2. Aguirre-Ghiso J.A. Models, mechanisms and clinical evidence for cancer dormancy. Nat. Rev. 2007, 7:834-846.
3. Aicher A., Kollet O., Heeschen C., Liebner S., Urbich C., Ihling C., Orlandi A., Lapidot T., Zeiher A.M., Dimmeler S. The Wnt antagonist Dickkopf-1 mobilizes vasculogenic progenitor cells via activation of the bone marrow endosteal stem cell niche. Circ. Res. 2008, 103:796-803.
4. Almog N. Molecular mechanisms underlying tumor dormancy. Cancer Lett. 2010, 294:139-146.
5. Aufderheide E., Ekblom P. Tenascin during gut development: appearance in the mesenchyme, shift in molecular forms, and dependence on epithelial-mesenchymal interactions. J.Cell Biol. 1988, 107:2341-2349.
6. Barbolina M.V., Liu Y., Gurler H., Kim M., Kajdacsy-Balla A.A., Rooper L., Shepard J., Weiss M., Shea L.D., Penzes P., et al. Matrix rigidity activates Wnt signaling through down-regulation of Dickkopf-1 protein. J.Biol. Chem. 2013, 288:141-151.
7. Bass M.D., Humphries M.J. Cytoplasmic interactions of syndecan-4 orchestrate adhesion receptor and growth factor receptor signalling. Biochem. J. 2002, 368:1-15.
8. Bissell M.J., Labarge M.A. Context, tissue plasticity, and cancer: are tumor stem cells also regulated by the microenvironment?. Cancer Cell 2005, 7:17-23.
9. Chiquet-Ehrismann R., Mackie E.J., Pearson C.A., Sakakura T. Tenascin: an extracellular matrix protein involved in tissue interactions during fetal development and oncogenesis. Cell 1986, 47:131-139.
10. De Langhe S.P., Sala F.G., Del Moral P.M., Fairbanks T.J., Yamada K.M., Warburton D., Burns R.C., Bellusci S. Dickkopf-1 (DKK1) reveals that fibronectin is a major target of Wnt signaling in branching morphogenesis of the mouse embryonic lung. Dev. Biol. 2005, 277:316-331.
11. De Laporte L., Rice J.J., Tortelli F., Hubbell J.A. Tenascin C promiscuously binds growth factors via its fifth fibronectin type III-like domain. PLoS ONE 2013, 8:e62076.
12. Forsberg E., Hirsch E., Fröhlich L., Meyer M., Ekblom P., Aszodi A., Werner S., Fässler R. Skin wounds and severed nerves heal normally in mice lacking tenascin-C. Proc. Natl. Acad. Sci. USA 1996, 93:6594-6599.
13. Gineitis D., Treisman R. Differential usage of signal transduction pathways defines two types of serum response factor target gene. J.Biol. Chem. 2001, 276:24531-24539.
14. Glinka A., Wu W., Delius H., Monaghan A.P., Blumenstock C., Niehrs C. Dickkopf-1 is a member of a new family of secreted proteins and functions in head induction. Nature 1998, 391:357-362.
15. Hanahan D. Heritable formation of pancreatic beta-cell tumours in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes. Nature 1985, 315:115-122.
16. Hanahan D., Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996, 86:353-364.
17. Hanahan D., Christofori G., Naik P., Arbeit J. Transgenic mouse models of tumour angiogenesis: the angiogenic switch, its molecular controls, and prospects for preclinical therapeutic models. Eur. J. Cancer 1996, 32A:2386-2393.
18. Herzig M., Savarese F., Novatchkova M., Semb H., Christofori G. Tumor progression induced by the loss of E-cadherin independent of beta-catenin/Tcf-mediated Wnt signaling. Oncogene 2007, 26:2290-2298.
19. Huang W., Chiquet-Ehrismann R., Moyano J.V., Garcia-Pardo A., Orend G. Interference of tenascin-C with syndecan-4 binding to fibronectin blocks cell adhesion and stimulates tumor cell proliferation. Cancer Res. 2001, 61:8586-8594.
20. Huijbers E.J., Ringvall M., Femel J., Kalamajski S., Lukinius A., Abrink M., Hellman L., Olsson A.K. Vaccination against the extra domain-B of fibronectin as a novel tumor therapy. FASEB J. 2010, 24:4535-4544.
21. Kerbel R.S. Tumor angiogenesis. N.Engl. J. Med. 2008, 358:2039-2049.
22. Lange K., Kammerer M., Hegi M.E., Grotegut S., Dittmann A., Huang W., Fluri E., Yip G.W., Götte M., Ruiz C., Orend G. Endothelin receptor type B counteracts tenascin-C-induced endothelin receptor type A-dependent focal adhesion and actin stress fiber disorganization. Cancer Res. 2007, 67:6163-6173.
23. Lange K., Kammerer M., Saupe F., Hegi M.E., Grotegut S., Fluri E., Orend G. Combined lysophosphatidic acid/platelet-derived growth factor signaling triggers glioma cell migration in a tenascin-C microenvironment. Cancer Res. 2008, 68:6942-6952.
24. Levental K.R., Yu H., Kass L., Lakins J.N., Egeblad M., Erler J.T., Fong S.F., Csiszar K., Giaccia A., Weninger W., et al. Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell 2009, 139:891-906.
25. Liao Y.L., Sun Y.M., Chau G.Y., Chau Y.P., Lai T.C., Wang J.L., Horng J.T., Hsiao M., Tsou A.P. Identification of SOX4 target genes using phylogenetic footprinting-based prediction from expression microarrays suggests that overexpression of SOX4 potentiates metastasis in hepatocellular carcinoma. Oncogene 2008, 27:5578-5589.
26. Lu P., Weaver V.M., Werb Z. The extracellular matrix: a dynamic niche in cancer progression. J.Cell Biol. 2012, 196:395-406.
27. Menezes M.E., Mitra A., Shevde L.A., Samant R.S. DNAJB6 governs a novel regulatory loop determining Wnt/β-catenin signalling activity. Biochem. J. 2012, 444:573-580.
28. Metz D.C., Jensen R.T. Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors. Gastroenterology 2008, 135:1469-1492.
29. Midwood K.S., Valenick L.V., Hsia H.C., Schwarzbauer J.E. Coregulation of fibronectin signaling and matrix contraction by tenascin-C and syndecan-4. Mol. Biol. Cell 2004, 15:5670-5677.
30. Midwood K.S., Orend G. The role of tenascin-C in tissue injury and tumorigenesis. J. Cell Commun. Signal 2009, 3:287-310.
31. Midwood K.S., Hussenet T., Langlois B., Orend G. Advances in tenascin-C biology. Cell. Mol. Life Sci. 2011, 68:3175-3199.
32. Mills G.B., Moolenaar W.H. The emerging role of lysophosphatidic acid in cancer. Nat. Rev. 2003, 3:582-591.
33. Min J.K., Park H., Choi H.J., Kim Y., Pyun B.J., Agrawal V., Song B.W., Jeon J., Maeng Y.S., Rho S.S., et al. The WNT antagonist Dickkopf2 promotes angiogenesis in rodent and human endothelial cells. J.Clin. Invest. 2011, 121:1882-1893.
34. Minn A.J., Kang Y., Serganova I., Gupta G.P., Giri D.D., Doubrovin M., Ponomarev V., Gerald W.L., Blasberg R., Massagué J. Distinct organ-specific metastatic potential of individual breast cancer cells and primary tumors. J.Clin. Invest. 2005, 115:44-55.
35. Miralles F., Posern G., Zaromytidou A.I., Treisman R. Actin dynamics control SRF activity by regulation of its coactivator MAL. Cell 2003, 113:329-342.
36. Murphy-Ullrich J.E., Lightner V.A., Aukhil I., Yan Y.Z., Erickson H.P., Höök M. Focal adhesion integrity is downregulated by the alternatively spliced domain of human tenascin. J.Cell Biol. 1991, 115:1127-1136.
37. Nevins J.R. The Rb/E2F pathway and cancer. Hum. Mol. Genet. 2001, 10:699-703.
38. Oh H., Ryu J.H., Jeon J., Yang S., Chun C.H., Park H., Kim H.J., Kim W.S., Kim H.H., Kwon Y.G., Chun J.S. Misexpression of Dickkopf-1 in endothelial cells, but not in chondrocytes or hypertrophic chondrocytes, causes defects in endochondral ossification. J.Bone Miner. Res. 2012, 27:1335-1344.
39. Orend G., Huang W., Olayioye M.A., Hynes N.E., Chiquet-Ehrismann R. Tenascin-C blocks cell-cycle progression of anchorage-dependent fibroblasts on fibronectin through inhibition of syndecan-4. Oncogene 2003, 22:3917-3926.
40. Oskarsson T., Acharyya S., Zhang X.H., Vanharanta S., Tavazoie S.F., Morris P.G., Downey R.J., Manova-Todorova K., Brogi E., Massagué J. Breast cancer cells produce tenascin C as a metastatic niche component to colonize the lungs. Nat. Med. 2011, 17:867-874.
41. Parangi S., O'Reilly M., Christofori G., Holmgren L., Grosfeld J., Folkman J., Hanahan D. Antiangiogenic therapy of transgenic mice impairs de novo tumor growth. Proc. Natl. Acad. Sci. USA 1996, 93:2002-2007.
42. Pendás-Franco N., Aguilera O., Pereira F., González-Sancho J.M., Muñoz A. Vitamin D and Wnt/beta-catenin pathway in colon cancer: role and regulation of DICKKOPF genes. Anticancer Res. 2008, 28(5A):2613-2623.
43. Pipas J.M., Levine A.J. Role of T antigen interactions with p53 in tumorigenesis. Semin. Cancer Biol. 2001, 11:23-30.
44. Reis M., Czupalla C.J., Ziegler N., Devraj K., Zinke J., Seidel S., Heck R., Thom S., Macas J., Bockamp E., et al. Endothelial Wnt/β-catenin signaling inhibits glioma angiogenesis and normalizes tumor blood vessels by inducing PDGF-B expression. J.Exp. Med. 2012, 209:1611-1627.
45. Ren S., Johnson B.G., Kida Y., Ip C., Davidson K.C., Lin S.L., Kobayashi A., Lang R.A., Hadjantonakis A.K., Moon R.T., Duffield J.S. LRP-6 is a coreceptor for multiple fibrogenic signaling pathways in pericytes and myofibroblasts that are inhibited by DKK-1. Proc. Natl. Acad. Sci. USA 2013, 110:1440-1445.
46. Ruiz C., Huang W., Hegi M.E., Lange K., Hamou M.F., Fluri E., Oakeley E.J., Chiquet-Ehrismann R., Orend G. Growth promoting signaling by tenascin-C [corrected]. Cancer Res. 2004, 64:7377-7385.
47. Schenk S., Muser J., Vollmer G., Chiquet-Ehrismann R. Tenascin-C in serum: a questionable tumor marker. Int. J. Cancer 1995, 61:443-449.
48. Smadja D.M., d'Audigier C., Weiswald L.B., Badoual C., Dangles-Marie V., Mauge L., Evrard S., Laurendeau I., Lallemand F., Germain S., et al. The Wnt antagonist Dickkopf-1 increases endothelial progenitor cell angiogenic potential. Arterioscler. Thromb. Vasc. Biol. 2010, 30:2544-2552.
49. Song S., Ewald A.J., Stallcup W., Werb Z., Bergers G. PDGFRbeta+ perivascular progenitor cells in tumours regulate pericyte differentiation and vascular survival. Nat. Cell Biol. 2005, 7:870-879.
50. Spencer J.A., Misra R.P. Expression of the SRF gene occurs through a Ras/Sp/SRF-mediated-mechanism in response to serum growth signals. Oncogene 1999, 18:7319-7327.
51. Tanaka K., Hiraiwa N., Hashimoto H., Yamazaki Y., Kusakabe M. Tenascin-C regulates angiogenesis in tumor through the regulation of vascular endothelial growth factor expression. Int. J. Cancer 2004, 108:31-40.
52. Tavazoie S.F., Alarcón C., Oskarsson T., Padua D., Wang Q., Bos P.D., Gerald W.L., Massagué J. Endogenous human microRNAs that suppress breast cancer metastasis. Nature 2008, 451:147-152.
53. van Obberghen-Schilling E., Tucker R.T., Saupe F., Gasser I., Cseh B., Orend G. Fibronectin and tenascin-C: accomplices in vascular morphogenesis during development and tumor growth. Int. J. Dev. Biol. 2011, 55:511-525.
54. Wenk M.B., Midwood K.S., Schwarzbauer J.E. Tenascin-C suppresses Rho activation. J.Cell Biol. 2000, 150:913-920.
55. Wu F.T., Stefanini M.O., Mac Gabhann F., Popel A.S. A compartment model of VEGF distribution in humans in the presence of soluble VEGF receptor-1 acting as a ligand trap. PLoS ONE 2009, 4:e5108.
56. Zhou A.D., Diao L.T., Xu H., Xiao Z.D., Li J.H., Zhou H., Qu L.H. β-Catenin/LEF1 transactivates the microRNA-371-373 cluster that modulates the Wnt/β-catenin-signaling pathway. Oncogene 2012, 31:2968-2978.